ClinicalTrials.gg
CompletedNCT06436183Updated Sep 18, 2025

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

A Phase 2 interventional study of Camoteskimab and Placebo in Atopic Dermatitis, Atopic and Dermatitis, sponsored by Apollo Therapeutics Ltd. Completed at 35 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by Apollo Therapeutics Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
316th of 544
62 · median 96
Started
2024
with 33 others
Phase 2
202 of 639
18 open now
Registered
549th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 316th largest by enrollment of the 544 interventional ones that give a count, is one of 34 that started in 2024, is one of 202 in phase 2, and was the 549th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.

Read the detailed description

This study contains two parts: Parts 1 and Part 2.

Part 1 (Blinded Period):

Eligible patients will be randomized in a 1:1:1 ratio to receive either camoteskimab dose 1, camoteskimab dose 2 or placebo.

Part 2 (Extension Period):

In part 2, all participants will receive camoteskimab.

03

Conditions studied

  • Atopic Dermatitis
  • Atopic
  • Dermatitis
  • Dermatologic Disease
  • Eczema
  • Eczema Atopic Dermatitis
  • Eczema, Atopic
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be 18-75 years of age inclusive, at the time of signing the .
  2. Chronic AD for at least 1 year.
  3. Participants with moderate to severe AD defined by:

    1. Investigator global assessment (IGA) score of ≥ 3 (on a scale of 0 to 4, in which three is moderate and four is severe) at Baseline.
    2. AD involvement of ≥ 10% body surface area (BSA) at Baseline.
    3. EASI score of ≥ 12 at Baseline.
    4. Pruritus numerical rating scale (NRS) ≥ 4 at Baseline.
  4. Participants who are candidates for systemic therapy, defined as inadequate response to treatment with topical medications, or for whom topical treatments are otherwise medically inadvisable.
  5. use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    Female participants:

    • Sexually active females of must agree to use two forms of accepted methods of highly effective forms of contraception during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes:
    • IUD plus one barrier method.
    • Stable doses of hormonal contraception for at least 3 months (e.g., oral, injectable, implant, transdermal) plus one barrier method.
    • 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm); or
    • A vasectomized partner*.

    Male participants:

    • Sexually active male participants and males and who are partners of females of childbearing potential agree to use two forms of contraception as above and to not donate sperm or try to conceive during the treatment period and for at least 3 months after the last dose of study drug.
  6. Participant provides signed informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Participant has history of use of more than two (2) prior systemic therapies for AD (e.g.

    biologics or JAKi) and who used any of these medications as follows:

    1. Dupilumab, tralokinumab, lebrikizumab within 8 weeks prior to Baseline.
    2. Systemic JAKi within 4 weeks prior to Baseline.
    3. TCS, TCI, topical phosphodiesterase-4 (PDE4) inhibitors, and topical JAKi within 7 days prior to enrollment (at Baseline) or more than five half-lives whichever is longer.
  2. Participant has a current diagnosis of other active skin disease (e.g., psoriasis or lupus erythematosus) or skin infection (bacterial, fungal, or viral) that may affect the evaluation of AD or would interfere with the study assessments.
  3. Participant has a severe comorbidity that may require systemic therapy or other interventions or requires active frequent monitoring (e.g., unstable chronic asthma).
  4. Any abnormalities in rhythm, conduction or morphology of the resting (ECG) and any clinically significant abnormalities in the 12- lead ECG as considered by the perfusion index that may interfere with the interpretation of changes.
  5. Participant has AD involving ocular symptoms, or blepharitis, conjunctivitis, or keratitis diagnosed within the last 60 days prior to the screening visit, requiring chronic ocular corticosteroid treatment.
  6. Participant has severe or uncontrolled seasonal or allergic rhinitis, asthma or any other non-AD disease as judged by the Investigator. Participants with seasonal or allergic rhinitis, asthma or any other non-AD disease requiring use of intranasal or inhaled corticosteroid that is stable and well-controlled are not excluded.
  7. Active (HIV): confirmed positive anti-HIV antibody (HIV Ab) test; Active virus (HBV): confirmed hepatitis B surface antigen (HBs Ag) positive (+) or hepatitis B core antibody (HBc Ab) positive (+); Active virus (HCV): Confirmed hepatitis C antibody positive (+); evidence of active or latent TB
  8. Diagnosed with a within 5 years of enrollment (suspected malignancy should be ruled out by blood or tissue , as applicable) with the exception of

    • Completely resected basal call or squamous cell carcinoma of the skin.
    • Carcinoma in situ of the cervix.
  9. Has had previous exposure to anti-IL-18 therapy.
  10. Treatment with any agent, or any investigational device or procedure, within 28 days (or 5 half- lives, whichever is greater) of screening.
  11. Has any of the following laboratory findings

    1. (GFR) \< 30 mL/min/1.73 m2.
    2. ≤8 g/dL.
    3. Neutrophils ≤1,500/μL.
    4. ≤75,000/μL.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Dose 1

    Camoteskimab

    Drug: Camoteskimab

  • Experimental
    Dose 2

    Camoteskimab

    Drug: Camoteskimab · Drug: Placebo

  • Placebo comparator
    Placebo

    Dummy version of the study drug

    Drug: Placebo

Interventions

  • Drug Product

    Also known as: APL-9109, AVTX-007, CERC-007, AEVI-007, MEDI2338

  • DrugPlacebo

    Inactive substance

06

What researchers measure

Primary outcomes

  1. Percentage change from baseline in Eczema Area and Severity Index (EASI) between camoteskimab and placebo at Week 12

    An EASI score is a tool used to measure the extent (area) and severity of atopic eczema. The EASI utilizes area assessments that rate the four involved regions on a 0% to 100% scale for each region. The scores are added up for each of the four body regions (head, arms, trunk, and legs). For each of these components, the individual scores are added together to calculate the EASI score, which ranges from 0 to 72. The higher the EASI score, the more severe the AD.

    Time frame: 12 weeks

Secondary outcomes

  1. Percent change from baseline in EASI score at Week 12

    To further assess the efficacy of camoteskimab in participants with AD via the Eczema Area and Severity Index (EASI) which measures the severity of clinical signs in atopic dermatitis (AD).

    Time frame: 12 Weeks

  2. Change from baseline in EASI score at Week 12

    To further assess the efficacy of camoteskimab in participants with AD via the Eczema Area and Severity Index (EASI) which measures the severity of clinical signs in atopic dermatitis (AD).

    Time frame: 12 weeks

  3. Proportion of participants achieving a 50, 75, 90 and 100% improvement from baseline in EASI (EASI-50, 75, 90 and 100) at Week 12

    To further assess the efficacy of camoteskimab in participants with AD via the Eczema Area and Severity Index (EASI) which measures the severity of clinical signs in atopic dermatitis (AD).

    Time frame: 12 weeks

  4. Proportion of participants with an IGA 0/1 and a decrease in IGA of ≥ 2 points at Week 12

    To further assess the efficacy of camoteskimab in participants with AD via Investigator's Global Assessment Scale (IGA), which provides a global clinical assessment of AD severity.

    Time frame: 12 weeks

  5. Change from baseline in peak pruritus score at Week 12

    To further assess the efficacy of camoteskimab in participants with AD via the Pruritus Numerical Rating Scale, which assesses itch severity.

    Time frame: 12 weeks

  6. Proportion of participants with an improvement of ≥ 4 or more points in peak pruritus weekly score at Week 12

    To further assess the efficacy of camoteskimab in participants with AD via the Pruritus Numerical Rating Scale, which assesses itch severity.

    Time frame: 12 weeks

  7. Change from baseline in POEM score at Week 12

    To further assess the efficacy of camoteskimab in participants with AD via the Patient-Oriented Eczema Measure (POEM) which assesses disease systems.

    Time frame: 12 weeks

  8. Change from baseline in DLQI score at Week 12

    To further assess the efficacy of camoteskimab in participants with AD via the Dermatology Life Quality Index (DLQI) which assesses quality of life.

    Time frame: 12 weeks

  9. Change from baseline in AD involvement by BSA at Week 12

    To further assess the efficacy of camoteskimab in participants with AD via Body Surface Area (BSA) which assesses the percentage of the total skin affected by AD.

    Time frame: 12 weeks

  10. Change from baseline in SP-NRS at Week 12

    To further assess the efficacy of camoteskimab in participants with AD via the Skin Pain Numerical Rating Scale (SP-NRS) which assesses skin pain.

    Time frame: 12 weeks

  11. Change from baseline in PROMIS-SRI-SF-8a score at Week 12 reported outcomes

    To further assess the efficacy of camoteskimab in participants with AD via Patient Reported Outcomes Measurement Information System (PROMIS) which measures patient-reported health status for physical, mental, and social well-being.

    Time frame: 12 weeks

07

Study locations

35 sites
  • Medical Dermatology Specialists, PC/US Dermatology Partners
    Phoenix, Arizona 85006, United States
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • First OC Dermatology Research, Inc.
    Fountain Valley, California 92708, United States
  • Center for Dermatology Clinical Research, Inc.
    Fremont, California 94538, United States
  • California Allergy and Asthma Medical Group
    Los Angeles, California 90025, United States
  • University of California Los Angeles Dermatology
    Los Angeles, California 90095, United States
  • Amicis Research Center (Northridge)
    Northridge, California 91324, United States
  • Cura Clinical Research
    Oxnard, California 93030, United States
  • VASDHS - Veterans Affairs San Diego Medical Center
    San Diego, California 92161, United States
  • Clinical Sciences Institute
    Santa Monica, California 90404, United States
  • Renaissance Research and Medical Group
    Cape Coral, Florida 33991, United States
  • D&H National Research Centers, Inc.
    Miami, Florida 33155, United States
  • Avita Clinical Research - Dermatology
    Tampa, Florida 33613, United States
  • Sneeze, Wheeze & Itch Associates, LLC
    Normal, Illinois 61761, United States
  • Dawes Fretzin Clinical Research
    Indianapolis, Indiana 46250, United States
  • Skin Sciences, PLLC
    Louisville, Kentucky 40217, United States
  • Owensboro Dermatology Associates
    Owensboro, Kentucky 42303, United States
  • Revival Research Institute
    Troy, Michigan 48084, United States
  • Somerset Skin Centre
    Troy, Michigan 48084, United States
  • Michigan Dermatology Institute
    Waterford, Michigan 28329, United States
  • Advanced Dermatology and Skin Cancer Center - Saint Joseph
    Saint Joseph, Missouri 64506, United States
  • Skin Specialists PC
    Omaha, Nebraska 68144, United States
  • M3 Wake Research, Inc.
    Raleigh, North Carolina 27612, United States
  • ObjectiveHealth-The Skin Surgery Center for Clinical Research
    Winston-Salem, North Carolina 27103, United States
  • Central Sooner Research
    Oklahoma City, Oklahoma 73071, United States
  • Unity Clinical Research - Dermatology
    Oklahoma City, Oklahoma 73118, United States
  • Paddington Testing Co. Inc
    Philadelphia, Pennsylvania 19103, United States
  • Rodgers Dermatology
    Frisco, Texas 75034, United States
  • Center for Clinical Studies
    Houston, Texas 77004, United States
  • Clinical Trial Network
    Houston, Texas 77074, United States
  • Youthful Image
    Edmonton, Alberta T5J 3S9, Canada
  • Rejuvenation Dermatology Clinic Edmonton South
    Edmonton, Alberta T6W 0J5, Canada
  • Kingsway Clinical Research
    Etobicoke, Ontario M8X 1Y9, Canada
  • Clinique Medicale Saint-Louis
    Québec, Quebec G1W 4R4, Canada
  • Clinique Dermatologique de Sherbrooke
    Sherbrooke, Quebec J1G 1X9, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Mar 2025, 10 months.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 10 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2024
First posted
May 30, 2024
StartActual
May 1, 2024
Primary completionActual
Mar 26, 2025
CompletionActual
Aug 12, 2025
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06436183
Lead sponsor
Apollo Therapeutics Ltd
Responsible party
Sponsor
First posted
May 30, 2024
Start date
May 1, 2024
Primary completion
Mar 26, 2025
Completion
Aug 12, 2025
Last update
Sep 18, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camoteskimab

Start the discussion